Invasive mucormycosis in a tertiary care hospital in the western region of Saudi Arabia: 11-year retrospective chart review from 2009 to 2019

Almarhabi, Hassan; Al-Asmari, Essam; Munshi, Adeeb; Farahat, Faysal; Al-Amri, Abdulfatah; Al-Maghraby, Hatim; Alharbi, Malak; Althaqafi, Abulhakeem

doi:10.1016/j.jiph.2022.11.010

Cited by 3 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mortality rates, although variable in different series, remain quite high in recent reports, ranging from 29 to 73% [21, 49,50]. Despite common belief to the contrary, a study reported that immunocompetent patients with MCR in the setting of major trauma have comparable mortality rates to those seen in immunocompromised patients [51].…”

Section: Prognosismentioning

confidence: 99%

Mucormycosis: update on clinical presentation, diagnosis, and treatment

Dailey Garnes,

Kontoyiannis

2023

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of review Mucormycosis (MCR) is a common opportunistic mold infection, and Mucorales were recently designated by WHO as priority pathogens. The interest in this infection has risen significantly since the major outbreak of MCR in the context of the COVID-19 pandemic, particularly in India. Herein, we summarize recently (last 24 months) published information regarding clinical aspects of MCR. Recent findings The disease remains protean in its clinical presentation, difficult to diagnose, and challenging to treat. In 2021, cases of COVID-19-associated mucormycosis (CAM) exploded in India during COVID-19 and manifested primarily as sino-orbital or sino-cerebral disease. Its classic risk factors included the triad of COVID-19, uncontrolled diabetes mellitus and use of corticosteroids. Despite difficulties in the timely diagnosis of MCR, significant progress has been made with the use of molecular techniques in blood to assist with earlier diagnosis, which can facilitate earlier appropriate therapy and improve outcomes. In addition, advances have been made in the use of imaging to stage the disease, determining what types of multimodal therapy are required depending on staging, and tissue-based identification of Mucorales. Summary Although the outlook for MCR has improved, effective new antifungals, risk stratification, and the optimal multimodality approaches remain an unmet need.

show abstract

Section: Prognosismentioning

confidence: 99%